Use this URL to cite or link to this record in EThOS:
Title: The synthesis, characterisation, and formulation of novel organogermanium compounds as potential anticancer drugs
Author: Fosu-Mensah, Nelly Abena
ISNI:       0000 0004 5357 7700
Awarding Body: University of Reading
Current Institution: University of Reading
Date of Award: 2014
Availability of Full Text:
Access from EThOS:
The clinical applications of metal-based anticancer drugs are limited by their poor water solubility and stability, and shortfalls in their pharmacological activities. Recently, much emphasis has been placed on the use of drug targeting and delivery (DTD) systems in order to mitigate these drawbacks. One example of such DTD systems which is under intense scrutiny is the use of vector molecules, such as tamoxifen to achieve selective transport of a chemotherapeutic agent to cancer cells. Tamoxifen is a selective estrogen receptor modulator (SERM) used for the treatment of all stages of estrogen-dependent breast cancers. However, the clinical use of tamoxifen is also limited by the development of resistance and an increase in the incidence of endometrial cancer. Additionally, estrogen-independent breast cancers are also insensitive to tamoxifen. Consequently, it has been proposed that organometallic SERMs (tamoxifen- metal complex conjugate) could be an efficient target against both types of breast cancers, by exploiting the intrinsic activities of both the tamoxifen ligand and the metal complex. The work presented within this thesis builds on this concept by developing novel organogermanium-based SERMs as potential anticancer drugs. The organogermanium compound, germanium sesquioxide (Ge-132) was chosen to be coupled to tamoxifen analogues, as it has shown a range of biological activities including antitumour activity, both in vitro and in vivo with no detectable chronic toxicity or side effects.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available